

ESMO 2018 Industry Satellite Symposium

How immunotherapy is revolutionising first-line lung cancer care

Monday, 22 October 2018

13.00–14.30

ICM – Room 14b

Messe Munich
Munich, Germany

Considering the options with cancer immunotherapy in first-line NSCLC

Mark A. Socinski (USA)

Navigating between cancer immunotherapy regimens in non-squamous NSCLC

Patient profiles discussion

Fabrice Barlesi (France)

Putting it all into perspective: what does this mean for our patients?

Panel discussion: All faculty

A new era for patients with extensive-stage SCLC: evaluating the evidence

Martin Reck (Germany)

What are the clinical considerations for future treatment decisions in SCLC?

Panel discussion: All faculty

